Key Facts
General Information
Biocon Limited is a fully integrated biopharmaceutical company focused on biopharmaceuticals, custom research and clinical research.
Subsidiary Companies:
Syngene International Limited is a custom research organisation offering synthetic chemistry and molecular biology services for early stage drug discovery and development.
Clinigene International Limited is a clinical research organisation offering Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors.
Biocon Biopharmaceuticals Private Limited (BBPL) is a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines.
AxiCorp GmbH is a Friedrichsdorf (Germany) based pharmaceutical marketing company and is amongst the fastest growing in Europe. Biocon Limited acquired a majority stake in AxiCorp GmbH (70%) in February, 2008.
NeoBiocon FZ LLC is a research and marketing pharmaceutical company based in Abu Dhabi. Incorporated in January 2008, NeoBiocon is a 50:50 joint venture with Dr. B.R.Shetty, Managing Director of NeoPharma, Abu Dhabi.
Intellectual Profile of 3600+ Personnel
Biocon, Syngene and Clinigene together employee approximately 3600 qualified personnel - from biologists, chemists, medical practitioners, pharmacologists, engineers, finance/legal/marketing analysts, HR generalists to general administrators. 5% of our employees have PhD degrees, 41% have a master’s degree in science and the remaining are graduates with a bachelor's degree in science, commerce or arts. 15% of Biocon employees are women (across the group). The employee attrition last quarter was 7% and last year it was over 20%. The average age of the employees is 29 years.
Milestones
- Biocon is India's first biotechnology company, established
in 1978
- Biocon is India's first biotechnology company to export
microbial enzymes to USA and Europe
- Biocon is the first biotechnology company to receive ISO
9001 certification in India
- Syngene, a Biocon subsidiary, is India's first custom
research company in drug discovery
- Biocon is the first Indian company to be approved by
US FDA for the manufacture of lovastatin, a
cholesterol-lowering molecule
- Biocon's proprietary bioreactor, the PlaFractor™, receives a US patent
- Biocon's subsidiary, Clinigene, has India's first CAP
(College of American Pathologists) accredited clinical
research laboratory, setting the benchmark for
laboratories in India
- Biocon is awarded the Biotech Product and Process
Development and Commercialisation Award, 2001 by
the Department of Biotechnology, Ministry of Science
and Technology, Government of India
- Syngene is awarded the Certificate of Excellence for
Export Achievement by the Government of India, for
two consecutive years 2002-2003
- Biocon is the first company, globally to manufacture
human insulin, INSUGEN®, using a Pichia expression
system, 2004
- Biocon launches BIOMAb EGFR™ India's first anti-cancer, therapeutic Monoclonal Antibody-based drug for treating solid tumors of epithelial origin, such as head & neck cancers, 2006
- Biocon divests its enzymes division to Novozymes, focuses on biopharmaceuticals, 2007
- Syngene receives "BioServices Company of the Year",
BioSpectrum Awards, 2007
- Biocon's BIOMAb EGFR™ wins "Product of the Year",
BioSpectrum Awards, 2007
- Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30
Million, 2008
- Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte- colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future, 2008
- Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer, 2008
- Biocon is ranked among the top 20 global biotechnology companies (Med Ad News), 2008
- Biocon is the 7th largest biotech employer in the world (Med Ad News), 2008
- Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome, 2008
- NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer, 2008
- Biocon's Syngene partners with Sapient Discovery to expand integrated drug discovery offerings, 2009
- Biocon's Syngene and DuPont Crop Protection Forge Alliance Partnership, 2009
- Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park, 2009
- Biocon launches BASALOG - long lasting basal insulin for Type 1 & Type 2 Diabetics, 2009
- Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management, 2009
- Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market, 2009
Products
Biopharmaceuticals
Active Pharmaceutical Ingredients (APIs)
- Anti-Diabetic Agents
- Anti-Inflammatory Agents
- Anti-Oxidants
- Cardiovascular Agents
- Anti-Obesity Agents
- Digestive-Aid Enzymes
- Anti-Hypertensive Agents
- Haemostatic Agents
- Hepatoprotective Agents
- Immunosuppressants
- Gastro-Intestinal Agents
- Nutraceuticals
Biologicals
- Insulin
- Streptokinase
- EPO
- GCSF
- Monoclonal Antibodies
Branded Formulations
Oncology
- BIOMAb EGFR®
- NUFIL safe™ (Pre-filled Syringe)
- NUFIL™ (Vials)
- Abraxane® for injectable suspension
Nephrology
- ERYPRO safe™ (Pre-filled Syringe)
- TACROGRAF™
- RAPACAN™
- CYCLOPHIL ME™
- RENODAPT™
- RENODAPT™ - S
- CeRACaL™
Cardiology
- STATIX®
- STATIX®-F
- STATIX®-EZ
- BESTOR®
- TELMISAT™
- TELMISAT™-H
- ZARGO®
- ZARGO®-H
- ZIGPRIL®
- ACTIBLOK™-IPR
- BRADIA™
- CLASPRIN®
- THINRIN™
- MYOKINASE™
- CLOTIDE™
- DYNALIX®
Diabetology
- INSUGEN®-R
- INSUGEN®-N
- INSUGEN®-30/70
- INSUGEN®-50/50
- BASALOG™ 3ml, 10 ml
- BLISTO™ 1, 2 & 4
- BLISTO™-MF 1, 2 & 4
- METADOZE-IPR® 500 & 850
- PIODART®
- PIODART®-MF
- TriGPM™
- ZUKER™-MF
- GABIL™
- GMAB™ Plus
- OLISAT™
Dosage Forms
Biocon offers Indian pharmaceutical companies finished dosage formulations in the categories of cardiology, diabetology, nephrology, oncology and other specialised therapeutic segments. We provide formulations in the form of tablets, capsules, injections, liquid-orals and pellets.
Services
Licensing
Biocon collaboratively develops MAbs (Monoclonal Antibodies) and other novel drug delivery systems-based proteins either in-house or in partnership with other companies.
Contract Manufacturing
Biocon leverages its India cost base together with its extensive expertise and technology platforms to offer competitive, high quality, custom manufacturing services to a global clientele.
Research Services
| Custom Research - Syngene |
Chemistry
- Medicinal Chemistry
- Library Synthesis
- Process R&D
- Custom Manufacturing
- Analytical Services
- Polymer Chemistry
|
Biology
- Molecular Biology
- Protein Sciences
- Cell Lines Services
- Assay Services
- eADME/T&PK Studies
- Biologics
|
| |
| Clinical Research - Clinigene |
- Clinical Operations
- Clinical Development
- Clinical Data Management and Biostatistics
- Regulatory Services
- Human Pharmacology unit
- Bioanalytical Research Laboratory
- Central Laboratory
|
Contact
Corporate Headquarters
20th KM Hosur Road
Electronics City
Bangalore 560 100
India
Phone: 91 80 2808 2808 / 91 80 4014 4014
Fax: 91 80 2852 3423
Email: contact.us@biocon.com
Overseas Representative Office
New Jersey
485 Route 1 South
Woodbridge Corporate Plaza
Building B Suite 305 lselin,
NJ 08830, USA
Phone: 732 636 2950
Fax: 732 636 2951
Email: abhijit.zutshi@biocon.com
London
Biocon Limited
50, Elm Quay Court
30, Nine Elms Lane
SW8 5DF, London
Phone: +44 2078199788
Fax: +44 2074502980
Mobile: +44 7515962466
Email: nehal.vora@biocon.com
Abu Dhabi
NeoBiocon
P.O. Box 72900
Abu Dhabi
United Arab Emirates
Phone: +971-2-550 1000
Fax: +971 -2- 550 1199
Mobile: +971 50 5826489
Email: sumit.bhanot@biocon.com
Human Resources
For careers at Biocon, please contact us at:
Phone: 91 80 2808 2808 / 91 80 4014 4014
Email: human.resources@biocon.com
Licensing/ Collaboration Opportunities
To submit licensing/collaboration opportunities
enquiries, please contact:
Mr. Sandeep Rao
General Manager - Business Development
Phone: 91 80 2808 2070
Email: sandeep.rao@biocon.com
Investor Relations
For investor related queries please contact:
Mr. Kiran Kumar
Company Secretary
Phone: 91 80 2808 2037
Email: investor.relations@biocon.com
Corporate Communications
For media related queries, please contact:
Ms. Paula Sengupta
Head - Corporate Communications
Phone: 91 80 2808 2808 / 91 80 4014 4014
Email: corporate.communications@biocon.com
Top
|
